{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:57:23Z","timestamp":1788872243831,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T00:00:00Z","timestamp":1399593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n Currently, the only standard systemic treatment for advanced hepatocellular carcinoma is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the novel combination of sorafenib and gemcitabine in the treatment of advanced hepatocellular carcinoma.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Between\n M<\/jats:styled-content>\n arch 2008 and\n O<\/jats:styled-content>\n ctober 2010, patients with advanced pathologically proven hepatocellular carcinoma who had not received previous systemic therapy and had\n C<\/jats:styled-content>\n hild\u2013\n P<\/jats:styled-content>\n ugh liver function class\n A<\/jats:styled-content>\n or\n B<\/jats:styled-content>\n received sorafenib plus gemcitabine. Treatment included 4\u2010week cycle of gemcitabine (1000\u2009mg\/m\n 2<\/jats:sup>\n days 1, 8, 15) to the maximum of six cycles together with sorafenib (400\u2009mg twice daily). Patient continued sorafenib until disease progression or withdrawal from other reasons. The primary end point is progression\u2010free survival.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Forty\u2010five patients were enrolled in this study. The median progression\u2010free survival was 3.7 months (95%\n CI<\/jats:styled-content>\n 3.5\u20133.8). The overall response rate was 4% with no complete responses and the disease control rate was 66%. The median overall survival (OS) was 11.6 months (95%\n CI<\/jats:styled-content>\n 7.4\u201315.9). The median time to progression was 3.6 months (95%\n CI<\/jats:styled-content>\n 3.4\u20133.7). The most frequently reported grade 3\/4 treatment\u2010related adverse events included thrombocytopenia 33%, neutropenia 16% and hand\u2010foot skin reaction 13%. The study regimen was well tolerated.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The combination of sorafenib and gemcitabine in advanced hepatocellular carcinoma is generally well tolerated and has modest clinical efficacy. The median\n OS<\/jats:styled-content>\n is up to 1 year. However, well\u2010designed randomized controlled trials with a sorafenib alone comparator arm are needed to confirm this finding.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ajco.12191","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T01:38:39Z","timestamp":1399599519000},"page":"255-260","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open\u2010label, single\u2010arm phase\n II<\/scp>\n study"],"prefix":"10.1111","volume":"10","author":[{"given":"Vichien","family":"Srimuninnimit","sequence":"first","affiliation":[{"name":"Department of Medicine Faculty of Medicine Siriraj Hospital Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virote","family":"Sriuranpong","sequence":"additional","affiliation":[{"name":"Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthida","family":"Suwanvecho","sequence":"additional","affiliation":[{"name":"Bumrungrad International Hospital Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,9]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Cancer Facts & Figures 2010","author":"American Cancer Society","year":"2010"},{"key":"e_1_2_6_3_1","first-page":"3","article-title":"Cancer incidence and mortality in France over the period 1978\u20132000","volume":"51","author":"Remontet L","year":"2003","journal-title":"Rev Epidemiol Sante Publique"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.1.10"},{"key":"e_1_2_6_5_1","unstructured":"National Cancer Institute.SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer [Internet].2009. [Cited 30 Nov 2011.] Available from URL:http:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn134"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481001700207"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1672"},{"key":"e_1_2_6_11_1","first-page":"863","article-title":"The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal\u2010regulated and checkpoint kinases","volume":"20","author":"Matsumoto K","year":"2008","journal-title":"Oncol Rep"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22532"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11869"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP42650"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24029"},{"key":"e_1_2_6_17_1","first-page":"1676","article-title":"Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma","volume":"5","author":"Leung TW","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0837-7"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12191","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:29:43Z","timestamp":1696325383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/ajco.12191"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12191","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,9]]}}}